Colon cancer cell surface marker

"Colon cancer cell surface marker" is not a single molecular entity but refers to a group of proteins expressed on the plasma membrane of colon or colorectal cancer cells. These molecules are used as biomarkers for diagnosis, prognosis, patient stratification, and as potential therapeutic targets. Commonly studied colon cancer cell surface markers include:\n\nEpCAM – an epithelial adhesion molecule highly expressed on most colorectal adenocarcinomas but less so on normal tissue; widely used for immunohistochemical diagnosis and detection of circulating tumor cells.[6]\nCD44 – a glycoprotein involved in cellular adhesion and migration; overexpressed in many cancers including colon cancer, with roles in stemness and metastasis.[4][3]\nCD133/Prominin‑1 – recognized as a stem-cell associated antigen implicated in early detection and poor prognosis.[3]\nOther validated targets include EGFR, HER2, HER3, CLDN1, GPR56, LY6G6D/F, SLCO1B3, TLR4,[1][5] as well as cytokeratins such as CK20.\n\nThese markers are variably expressed depending on tumor subtype, location within the colon, genetic background such as KRAS mutation status,[5] or differentiation state. Some—like EpCAM—are primarily diagnostic tools; others—like EGFR—are direct drug targets. The heterogeneity of their expression poses challenges for universal targeting.\n\nBecause "Colon cancer cell surface marker" is not itself a unique molecule but rather an umbrella term encompassing several distinct proteins with different biological functions and clinical utilities,[1][2][3], this entry should be considered non-canonical unless further specified by the exact molecular target intended.

Other names

Colorectal cancer cell surface markerCRC cell surface markerColon adenocarcinoma cell surface markerColorectal carcinoma biomarker

Inhibition of receptor tyrosine kinase signaling pathways by monoclonal antibodies against EGFR or HER2[5]\nAntibody-dependent cellular cytotoxicity for some targeted therapies[5]